Effect of diet and exercise treatment for obese Japanese children on abdominal fat distribution

Kenji Togashi1, Hidenari Masuda, Kousei Iguchi

  • 1Department of Physical Education, Faculty of Education, Mie University, 1577 Kurimamachiya-cho, Tsu, Mie, 514-8507, Japan. togashi@edu.mie-u.ac.jp

Insights

Combined diet and exercise significantly reduced abdominal fat and chronic disease risk factors in obese Japanese children. This intervention improved body composition and metabolic health.

Area of Science:

  • Pediatric Endocrinology
  • Obesity Research
  • Metabolic Syndrome

Background:

  • Childhood obesity is a growing concern, particularly in Japan.
  • Obesity is linked to increased risk factors for chronic diseases.
  • Abdominal fat distribution is a key indicator of metabolic risk.

Purpose of the Study:

  • To evaluate the combined impact of dietary and exercise interventions on abdominal fat.
  • To assess the effects on chronic disease risk factors in obese Japanese children.

Main Methods:

  • 33 obese Japanese children participated in a 3-month supervised program.
  • Interventions included supervised exercise (5-7 days/week) and calorie-controlled diets (1400-1900 kcal/day).
  • Abdominal fat (subcutaneous and visceral) was measured via CT scans; blood markers (lipids, glucose, liver enzymes, uric acid) were analyzed.

Main Results:

  • Significant reductions in both subcutaneous and visceral abdominal fat areas were observed.
  • Key risk factors, including triglycerides, total cholesterol, insulin, AST, ALT, and uric acid, were markedly decreased.
  • The combined intervention demonstrated a positive effect on body composition and metabolic health markers.

Conclusions:

  • Dietary treatment combined with exercise is effective in managing abdominal obesity in children.
  • This integrated approach successfully reduces multiple risk factors for chronic diseases.
  • The findings support lifestyle interventions for improving health outcomes in pediatric obesity.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...